中国人群中ERCC1和ERCC2基因的遗传多态性与骨肉瘤患者化疗反应的相关性：一项荟萃分析
Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis.
作者信息
Zhang Haiguang, Ge Junbo, Hong Huanyu, Bi Lili, Sun Zhengwen
机构信息
Yantaishan Hospital, No. 91 Jiefang Road, 264000, Yantai City, Shandong Province, China.
Yeda Hospital, 264000, Yantai, Shandong Province, China.
出版信息
World J Surg Oncol. 2017 Apr 7;15(1):75. doi: 10.1186/s12957-017-1142-3.
BACKGROUND
There existed controversies about the association between the response to chemotherapy for osteosarcoma (OS) patients and the genetic polymorphisms in excision repair cross-complementation group (ERCC1 and ERCC2) genes. We aimed to perform a meta-analysis to comprehensively evaluate the association.
METHOD
We searched multiple databases for literature retrieval including the PubMED (1966 ∼ 2017), Embase (1980 ∼ 2017), and the Web of science (1945 ∼ 2017). The overall odds ratios(OR) and their corresponding 95% confidence interval (CI) were calculated for the three polymorphisms under the dominant, recessive, and allelic models.
RESULTS
From six eligible articles in our study, we found that for ERCC1 rs11615 polymorphism, a significant association was detected between the chemotherapy response and the polymorphism under all three models (dominant model: OR = 2.015, P = 0.005; recessive model: OR = 1.791, P = 0.003; allelic model: OR = 1.677, P = 0.003), and OS patients carrying C allele in rs11615 polymorphism were more likely to response to chemotherapy. In terms of ERCC2 rs1799793 polymorphism, this polymorphism was significantly associated with the response to chemotherapy for OS patients under recessive model (OR = 1.337, P = 0.036), and patients with AG + AA genotype in rs1799793 polymorphism were more appropriate to receive chemotherapy. With respect to ERCC2 rs13181 polymorphism, this polymorphism was not correlated with the response to chemotherapy for OS patients under all three models.
CONCLUSIONS
Our meta-analysis suggested that among Chinese population, the rs11615 and rs1799793 polymorphisms were significantly correlated with the response to chemotherapy for patients with OS, and patients with CC or TC + CC genotypes in ERCC1 rs11615 polymorphism or AG + AA genotype in ERCC2 rs1799793 polymorphism were more suitable for chemotherapy.
背景
骨肉瘤（OS）患者化疗反应与切除修复交叉互补基因（ERCC1和ERCC2）的基因多态性之间的关联存在争议。我们旨在进行一项荟萃分析以全面评估这种关联。
方法
我们检索了多个数据库进行文献检索，包括PubMed（1966年至2017年）、Embase（1980年至2017年）和Web of science（1945年至2017年）。在显性、隐性和等位基因模型下计算三种多态性的总体比值比（OR）及其相应的95%置信区间（CI）。
结果
在我们研究的六篇合格文章中，我们发现对于ERCC1 rs11615多态性，在所有三种模型下化疗反应与多态性之间均检测到显著关联（显性模型：OR = 2.015，P = 0.005；隐性模型：OR = 1.791，P = 0.003；等位基因模型：OR = 1.677，P = 0.003），并且rs11615多态性中携带C等位基因的OS患者更有可能对化疗有反应。对于ERCC2 rs1799793多态性，在隐性模型下该多态性与OS患者的化疗反应显著相关（OR = 1.337，P = 0.036），并且rs1799793多态性中AG + AA基因型的患者更适合接受化疗。关于ERCC2 rs13181多态性，在所有三种模型下该多态性与OS患者的化疗反应均无相关性。
结论
我们的荟萃分析表明，在中国人群中，rs11615和rs1799793多态性与OS患者的化疗反应显著相关，并且ERCC1 rs11615多态性中CC或TC + CC基因型或ERCC2 rs1799793多态性中AG + AA基因型的患者更适合化疗。
Zotero 插件